It looks like you're accessing our website from North America. We have a dedicated page tailored to your region, offering the most relevant information and services.
If you have an existing eCom account, you can log in to the North American site using your current username and password.
Would you like to visit the North America page?
You can access the page here
Recent data regarding BNP instability in circulation suggests that immunoassays utilizing at least one MAb specific to the terminal epitope could underestimate the real BNP content in the blood sample.
B-type natriuretic peptide (Brain natriuretic peptide, BNP) is an acknowledged marker of heart failure (HF) widely used in clinical practice for HF diagnosis and patient management.
The majority of BNP assays are designed as sandwich-type immunoassays utilizing two mAbs specific to distantly located epitopes. In commercially available assays at least one of these two antibodies is specific to the ring structure, while the other is usually specific to the C-terminus of the BNP molecule. Recent data regarding BNP instability in circulation suggests that immunoassays utilizing at least one MAb specific to the terminal epitope could underestimate the real BNP content in the blood sample.
CLINICAL UTILITY OF BNP
BENEFITS OF SES-BNP™ ASSAY